These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26393392)

  • 21. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The innovative medicines initiative: a case study for new ways of working in drug R&D.
    Laverty H; Goldman M
    Future Med Chem; 2014 Apr; 6(5):489-91. PubMed ID: 24649951
    [No Abstract]   [Full Text] [Related]  

  • 23. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.
    Martinez-Grau MA; Alvim-Gaston M
    Pharmaceut Med; 2019 Jun; 33(3):193-198. PubMed ID: 31933287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Professional translational research: a new hybrid paradigm in early drug discovery.
    Nussbaumer P; Klebl B
    Future Med Chem; 2015; 7(14):1879-89. PubMed ID: 26420644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia].
    Iida K; Yano T; Ikemori M; Ishida T; Nishimura N
    Yakugaku Zasshi; 2021 Jun; 141(6):877-886. PubMed ID: 33642438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards new business models for R&D for novel antibiotics.
    So AD; Gupta N; Brahmachari SK; Chopra I; Munos B; Nathan C; Outterson K; Paccaud JP; Payne DJ; Peeling RW; Spigelman M; Weigelt J
    Drug Resist Updat; 2011 Apr; 14(2):88-94. PubMed ID: 21439891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
    Thomas CE; Will Y
    Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.
    Wellenreuther R; Keppler D; Mumberg D; Ziegelbauer K; Lessl M
    Drug Discov Today; 2012 Nov; 17(21-22):1242-8. PubMed ID: 22521665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open-access public-private partnerships to enable drug discovery--new approaches.
    Müller S; Weigelt J
    IDrugs; 2010 Mar; 13(3):175-80. PubMed ID: 20191434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of external innovation on new drug approvals: A retrospective analysis.
    Liu X; Thomas CE; Felder CC
    Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. R&D: Antibiotic partners promote discovery.
    Bakken JS
    Nature; 2016 Sep; 537(7619):167. PubMed ID: 27604939
    [No Abstract]   [Full Text] [Related]  

  • 32. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 33. Into the valley of death: research to innovation.
    Hudson J; Khazragui HF
    Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schrödinger's pipeline and the outsourcing of pharmaceutical innovation.
    McMeekin P; Lendrem DW; Lendrem BC; Pratt AG; Peck R; Isaacs JD; Jones D
    Drug Discov Today; 2020 Mar; 25(3):480-484. PubMed ID: 31835019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Public-private partnership: from there to here.
    Croft SL
    Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The importance of triaging in determining the quality of output from high-throughput screening.
    Jones P; McElroy S; Morrison A; Pannifer A
    Future Med Chem; 2015; 7(14):1847-52. PubMed ID: 26419190
    [No Abstract]   [Full Text] [Related]  

  • 38. Getting physical to fix pharma.
    Connelly PR; Vuong TM; Murcko MA
    Nat Chem; 2011 Aug; 3(9):692-5. PubMed ID: 21860457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.